European Patent Granted for Our AI Thermal Imaging Technology

We are proud to announce a major milestone for Singularity Biomed: the official grant of our European patent by the European Patent Office (EPO). Published today, April 29, 2026, in the European Patent Bulletin [2026/18], this concession is a tremendous validation of our ongoing commitment to innovation in the healthcare sector.

📄 The Patent Details

The patent, officially titled "METHOD TO EXTRACT LOCAL THERMAL FEATURES OF JOINT INFLAMMATION IN THERMAL IMAGING, AND DEVICE IMPLEMENTING SUCH A METHOD" (EP4089578), protects the core algorithms underlying our AI-based thermographic analysis.

This specific method of thermal image analysis has consistently yielded the best results throughout our entire R&D process, demonstrating exceptional accuracy and robustness in detecting and quantifying joint inflammation.

🛡️ Reinforcing Our Intellectual Property

Securing this European patent is a crucial step forward for our company. It significantly reinforces our intellectual property (IP) portfolio, shielding the unique technology that sets our solutions apart in the field of rheumatology.

By protecting our proprietary method, we ensure that we can continue to develop and safely deploy our AI-assisted thermography tools. This IP foundation is essential not only for our competitive advantage but also for building trust with our clinical and pharmaceutical partners.

💡 The Value of Our Method

Our AI-driven approach to thermal imaging is transforming how joint inflammation is assessed. By shielding the method that drives our highly successful indices (like ThermoJIS and ThermoDAI), we guarantee the continuation of our technology. It ensures that our automated, objective monitoring tools remain uniquely positioned to complement standard clinical assessments.

🚀 Looking Ahead

Innovation in medical technology requires rigorous science, extensive clinical validation, and strong IP protection. Today, we celebrate a significant achievement in that last pillar.

This patent provides us with a robust legal framework as we continue to scale our operations and advance our international validation efforts.